Basis: Trailing twelve months (TTM), to the latest fiscal quarter end. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on equity (ROE) high or low?
The return on equity (ROE) of -75.34% is 99% below its 5-year average of -37.78%, around the middle of its 5-year range (-164.05%–79.06%).
As of the fiscal period ended Tuesday, June 30, 2026. 9.11% above its 12-month average of -82.88%.
Trailing-twelve-month return on equity at each fiscal quarter end; no daily interpolation. Q4 FY2026 (2026-06-30): -75.34%.
RETURN ON EQUITY (ROE)
-75.34%
RETURN ON EQUITY (ROE) AVG TTM
-82.88%
RETURN ON EQUITY (ROE) AVG 3Y
-31.17%
RETURN ON EQUITY (ROE) AVG 5Y
-37.78%
RETURN ON EQUITY (ROE) AVG 10Y
-50.16%
RETURN ON EQUITY (ROE) AVG 15Y
-38.49%
RETURN ON EQUITY (ROE) AVG 20Y
-32.38%
CURRENT VS TTM AVG
+9.11%
CURRENT VS 3Y AVG
-141.70%
CURRENT VS 5Y AVG
-99.41%
CURRENT VS 10Y AVG
-50.20%
CURRENT VS 15Y AVG
-95.75%
CURRENT VS 20Y AVG
-132.69%
SECTOR MEDIAN · HEALTHCARE
-40.20%
median of 651 covered companies
CURRENT VS SECTOR MEDIAN
-87.41%
vs the sector median at left
Neuphoria Therapeutics Inc.
Market Cap
$18.86M
Return on Equity (ROE)
-75.34%
TTM Avg
-82.88%
3Y Avg
-31.17%
5Y Avg
-37.78%
Market Cap
$18.60M
Return on Equity (ROE)
N/A
TTM Avg
-3014.83%
3Y Avg
-1589.49%
5Y Avg
-1032.64%
Market Cap
$19.25M
Return on Equity (ROE)
-351.86%
TTM Avg
-122.41%
3Y Avg
-86.06%
5Y Avg
-64.41%
Market Cap
$18.90M
Return on Equity (ROE)
-136.36%
TTM Avg
-41.80%
3Y Avg
-1184.66%
5Y Avg
-795.29%
Market Cap
$19.95M
Return on Equity (ROE)
-2067.81%
TTM Avg
-13234.78%
3Y Avg
-6645.16%
5Y Avg
-6645.16%
Market Cap
$17.81M
Return on Equity (ROE)
-117.98%
TTM Avg
-84.94%
3Y Avg
-64.05%
5Y Avg
-76.29%
Market Cap
$17.19M
Return on Equity (ROE)
-54.45%
TTM Avg
-33.23%
3Y Avg
-44.23%
5Y Avg
-52.50%
Market Cap
$20.60M
Return on Equity (ROE)
-313.46%
TTM Avg
-251.20%
3Y Avg
-178.74%
5Y Avg
-144.62%
Market Cap
$17.01M
Return on Equity (ROE)
-71.57%
TTM Avg
-65.12%
3Y Avg
-85.39%
5Y Avg
-90.29%
| NAME | MARKET CAP | RETURN ON EQUITY (ROE) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Neuphoria Therapeutics Inc. (NEUP) | $18.86M | -75.34% | -82.88% | -31.17% | -37.78% |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.60M | N/A | -3014.83% | -1589.49% | -1032.64% |
| NextCure, Inc. (NXTC)vs › | $19.25M | -351.86% | -122.41% | -86.06% | -64.41% |
| P3 Health Partners Inc. (PIII)vs › | $18.90M | -136.36% | -41.80% | -1184.66% | -795.29% |
| Actuate Therapeutics Inc (ACTU)vs › | $19.95M | -2067.81% | -13234.78% | -6645.16% | -6645.16% |
| Cosmos Health Inc. (COSM)vs › | $17.81M | -117.98% | -84.94% | -64.05% | -76.29% |
| Lipocine Inc. (LPCN)vs › | $17.19M | -54.45% | -33.23% | -44.23% | -52.50% |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.60M | -313.46% | -251.20% | -178.74% | -144.62% |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.01M | -71.57% | -65.12% | -85.39% | -90.29% |
| PAVmed Inc. (PAVM)vs › | $16.98M | -34.50% | -796.82% | -138.82% | -407.45% |
ROE
-75.3%
ROA
-64.5%
ROE = Net Income / Total Shareholders' Equity
Return on equity measures how efficiently a company generates profit from shareholders' equity. Higher ROE indicates better capital efficiency.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON EQUITY (ROE) |
|---|---|
| 2026-06-30 | -75.34% |
| 2026-03-31 | -96.80% |
| 2025-12-31 | -56.28% |
| 2025-09-30 | -164.05% |
| 2025-06-30 | -21.96% |
| 2025-03-31 | 22.41% |
| 2024-12-31 | 15.73% |
| 2024-09-30 | 57.83% |
| 2024-06-30 | 79.06% |
| 2024-03-31 | 56.76% |
| 2023-12-31 | -8.22% |
| 2023-09-30 | -117.68% |
| 2023-06-30 | -96.67% |
| 2023-03-31 | -86.22% |
| 2022-12-31 | -76.72% |
| 2022-09-30 | -53.04% |
| 2022-06-30 | -40.01% |
| 2022-03-31 | -37.50% |
| 2021-12-31 | -50.40% |
| 2021-09-30 | -25.87% |
| 2021-06-30 | -18.39% |
| 2021-03-31 | -9.54% |
| 2020-12-31 | -2.96% |
| 2020-09-30 | -22.79% |
| 2020-06-30 | -81.13% |
| 2020-03-31 | -60.27% |
| 2019-12-31 | -72.54% |
| 2019-09-30 | -73.74% |
| 2019-06-30 | -84.99% |
| 2019-03-31 | -114.91% |
| 2018-12-31 | -244.64% |
| 2018-09-30 | -163.97% |
| 2018-06-30 | -207.73% |
| 2018-03-31 | -92.27% |
| 2017-12-31 | -24.30% |
| 2017-09-30 | -19.03% |
| 2017-06-30 | -20.70% |
| 2017-03-31 | -28.02% |
| 2016-12-31 | -66.14% |
| 2016-09-30 | -44.94% |
| 2016-06-30 | -51.39% |
| 2016-03-31 | -41.12% |
| 2015-12-31 | -59.32% |
| 2015-09-30 | -41.37% |
| 2015-06-30 | -71.07% |
| 2015-03-31 | -17.88% |
| 2014-12-31 | -0.24% |
| 2014-09-30 | 6.36% |
| 2014-06-30 | 11.90% |
| 2013-12-31 | 0.00% |
| 2013-06-30 | 0.00% |
| 2012-12-31 | 0.00% |
| 2012-06-30 | 0.00% |
| 2011-12-31 | 0.00% |
| 2011-06-30 | 0.00% |
| 2010-12-31 | 0.00% |
| 2010-06-30 | 0.00% |
| 2009-12-31 | 0.00% |
| 2009-06-30 | 0.00% |
| 2008-12-31 | 0.00% |
| 2008-06-30 | 0.00% |
| 2007-12-31 | 0.00% |
| 2007-06-30 | 0.00% |
| 2006-12-31 | 0.00% |
| 2006-06-30 | 0.00% |
| 2005-12-31 | 0.00% |
| 2005-06-30 | 0.00% |
